Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit .SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 10 a.m. EST in New York City, New York.
加州聖馬特奧，2024年11月26日（環球新聞通訊社）-- Sagimet Biosciences Inc.（Sagimet，納斯達克：SGMT）是一家臨牀階段的生物製藥公司，致力於開發針對功能性代謝和纖維化通路的 novel 療法，今天宣佈管理層將於2024年12月3日星期二上午10點（東部標準時間）在紐約市的派傑投資第36屆年度醫療會議上進行演講。
A webcast of the presentation will be available in the Investors & Media section of Sagimet's website at , with an archived replay available for 90 days following the live event.
演講的網絡直播將在Sagimet網站的投資者與媒體部分提供，活動結束後的90天內將提供存檔重播。
About Sagimet Biosciences
關於Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit .
Sagimet是一家臨牀階段的生物製藥公司，開發新型脂肪酸合成酶（FASN）抑制劑，旨在針對由於過量產生脂肪酸棕櫚酸而導致的代謝和纖維化通路失調的疾病。Sagimet的首個藥物候選者denifanstat是一種口服的每日一次的選擇性FASN抑制劑，正在開發用於治療與代謝功能障礙相關的脂肪性肝炎（MASH）。FASCINATE-2是一個Phase 20億的denifanstat在MASH中進行的臨牀試驗，其主要終點基於肝活檢，已成功完成並取得積極結果。Denifanstat已獲得FDA對中度至重度肝纖維化（與F2至F3階段一致）的非肝硬化性MASH治療的突破性療法認定，且與FDA的第2階段結束互動已成功完成，支持denifanstat進入MASH的第3階段開發。有關Sagimet的更多信息，請訪問。
Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
聯繫：
喬伊斯·阿萊爾
LifeSci顧問公司
jallaire@lifesciadvisors.com
Source: Sagimet Biosciences Inc.
來源：Sagimet生物科學公司。